Objective: To evaluate the clinical impact and cost-effectiveness of HLA-B Ã 5701 testing to guide selection of first-line HIV regimens in the United States. Design: Cost-effectiveness analysis using a simulation model of HIV disease. The prevalence of HLA-B Ã 5701 and the probabilities of confirmed and unconfirmed severe systemic hypersensitivity reaction among patients taking abacavir testing HLA-B Ã 5701 positive and negative were from the Prospective Randomized Evaluation of DNA Screening in a Clinical Trial study. The monthly costs of abacavir-based and tenofovir-based regimens were $1135 and $1139, respectively; similar virologic efficacy was assumed and this assumption was varied in sensitivity analysis. Patients: Simulated cohort of patients initiating HIV therapy. Interventions: The interventions are first-line abacavir, lamivudine, and efavirenz without pretreatment HLA-B Ã 5701 testing; the same regimen with HLA-B Ã 5701 testing; and first-line tenofovir, emtricitabine, and efavirenz. Main outcome measures: Quality-adjusted life years and lifetime medical costs discounted at 3% per annum, cost-effectiveness ratios ($/QALY). Results: Abacavir-based treatment without HLA-B Ã 5701 testing resulted in a projected 30.93 years life expectancy, 16.23 discounted quality-adjusted life years, and $472 200 discounted lifetime cost per person. HLA-B Ã 5701 testing added 0.04 quality-adjusted months at an incremental cost of $110, resulting in a cost-effectiveness ratio of $36 700/ QALY compared with no testing. Initiating treatment with a tenofovir-based regimen increased costs without improving quality-adjusted life expectancy. HLA-B Ã 5701 testing remained the preferred strategy only if abacavir-based treatment had equal efficacy and cost less per month than tenofovir-based treatment. Results were also sensitive to the cost of HLA-B Ã 5701 testing and the prevalence of HLA-B Ã 5701. Conclusion: Pharmacogenetic testing for HLA-B Ã 5701 is cost-effective only if abacavir-based treatment is as effective and costs less than tenofovir-based treatment. d Represents the quality-of-life decrement occurring in the last month of life compared with chronic HIV.
Background
Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) used as part of combination antiretroviral therapy (ART) for HIV. It has proven efficacy in first-line ART regimens, with few drug long-term toxicities observed [1] . In a small proportion of patients, however, treatment with abacavir may be associated with systemic hypersensitivity reaction (HSR), a multiorgan system process that can be severe enough to cause hospitalization or death [2] . Both retrospective and prospective studies [3, 4] have demonstrated a strong association between the presence of the HLA-B Ã 5701 allele and the risk of HSR in patients taking abacavir. Furthermore, in a randomized, prospective clinical trial, patients screened for HLA-B Ã 5701 before abacavir therapy experienced dramatically reduced rates of both clinically diagnosed and immunologically confirmed HSR [5] .
HIV treatment guidelines issued by the United States Department of Health and Human Services in February 2008 recommend abacavir as a preferred component of initial ART only for patients who test negative for HLA-B Ã 5701 [6] . Given the safety and efficacy of abacavirbased treatment in the absence of HSR, our goal was to evaluate the long-term clinical impact and costeffectiveness of pretreatment HLA-B Ã 5701 testing to guide initial HIV therapy.
Methods

Analytic overview
We used the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) model, a widely published simulation state transition model of HIV disease [7, 8] , along with data reported in the literature, to evaluate the clinical impact and cost-effectiveness of HLA-B Ã 5701 testing to guide selection of first-line HIV treatment regimens in patients in the United States. Upon entering the model, simulated patients initiated a first-line ART regimen consisting of a fixed-dose combination of abacavir and lamivudine with efavirenz or a fixed-dose combination of tenofovir, emtricitabine, and efavirenz. For patients initiating treatment that included abacavir, we compared 'universal testing' with 'no testing.' In the universal testing strategy, all patients were tested for HLA-B Ã 5701 prior to ART initiation. Abacavir-based treatment was selected for patients testing HLA-B Ã 5701 negative and tenofovir-based treatment was selected for patients testing HLA-B Ã 5701 positive. In the no testing strategy, all patients were initiated on abacavir-based treatment. In either strategy, patients taking abacavir who developed a suspected HSR were treated in office-based or inpatient settings according to the severity of their symptoms, and were then switched to tenofovir-based treatment. Patients switched to tenofovir-based treatment who subsequently developed treatment-limiting tenofovir-associated nephrotoxicity were switched to a fixed-dose combination of zidovudine and lamivudine with efavirenz.
In the comparison strategy, all patients in the model initiated tenofovir-based treatment without initial HLA-B Ã 5701 testing. For patients who developed treatmentlimiting tenofovir-associated nephrotoxicity, we considered three alternatives to guide drug substitution: 'substitution HLA-B Ã 5701 testing,' in which those testing HLA-B Ã 5701 negative were switched to abacavir-based treatment and those testing HLA-B Ã 5701 positive were switched to zidovudine-based treatment, substituting abacavir-based treatment without testing, and substituting zidovudine-based treatment without testing.
Model
We used the CEPAC model to project the long-term outcomes of each possible combination of initial drug regimens, toxicities (mild, severe, or fatal suspected HSR; treatment-limiting tenofovir-associated nephrotoxicity; or no toxicity), and drug substitutions. Details regarding the CEPAC model structure, data, and assumptions have been previously described (see Appendix at http://www. aidsonline.com). We then calculated the results for each strategy as the weighted average of these projected outcomes using probabilities derived from published studies as the basis for weighting. These probabilities included the incidence of immunologically confirmed HSR in patients taking abacavir with and without HLA-B Ã 5701 testing, and the reduction in suspected HSR diagnoses observed with HLA-B Ã 5701 testing. Tables 1 and 2 report baseline  model inputs and ranges used in sensitivity analyses. Results are reported as quality-adjusted life expectancies (QALYs) and lifetime direct medical costs in 2006 US dollars, both discounted to present value at an annual rate of 3%. All cost-effectiveness ratios are calculated on an incremental basis by ranking strategies from least to most expensive and comparing each strategy with the next most expensive strategy. Cost-effectiveness ratios are reported as cost per quality-adjusted life year ($/QALY).
Abacavir systemic hypersensitivity reaction data
On the basis of the results from the control group of the Prospective Randomized Evaluation of DNA Screening in a Clinical Trial (PREDICT-1) study, a randomized multicenter trial conducted in Europe and Australia to evaluate the efficacy of HLA-B Ã 5701 screening for HSR in patients taking abacavir, the probability of testing HLA-B Ã 5701 positive is 5.7% and the probability of immunologically confirmed HSR for HLA-B Ã 5701 positive patients taking abacavir is 2.7%. The rate of immunologically confirmed HSR is, therefore, 47.9% in HLA-B Ã 5701 positive patients. In PREDICT-1, none of the HLA-B Ã 5701 negative patients taking abacavir developed immunologically confirmed HSR [5] . Other studies indicate that 58.5% of all immunologically confirmed HSR cases are mild (grades 1 or 2) and 41.5% are severe (grade 3 or 4) [9] , and that 1.7% of the severe cases are fatal [2] . On the basis of the results of the PREDICT-1 trial, suspected HSR that would not be immunologically confirmed is diagnosed in 5.1% of patients taking abacavir when HLA-B Ã 5701 testing is unavailable and 3.4% when testing is available [5] . In sensitivity analyses, we examined different assumptions for a population with a race/ethnicity composition relevant to US clinical settings.
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Efficacy of antiretroviral regimens
In the primary analysis, the efficacy of first-line regimens was derived from a clinical trial in which 81% of patients treated with tenofovir and emtricitabine with efavirenz achieved HIV RNA less than 400 copies/ml at 48 weeks and the mean CD4 cell count increase was 190 cells/ml [10] . We assumed equivalent efficacy for abacavir and lamivudine with efavirenz, and varied this assumption in sensitivity analyses. On the basis of the same clinical trial results [10] , patients in the simulation who switched to zidovudine and lamivudine with efavirenz achieved a viral suppression rate of 70% with HIV RNA less than 400 copies/ml at 48 weeks and a mean CD4 cell count increase of 158 cells/ml. We used published clinical trial data to estimate the virologic efficacy of each of five subsequent lines of ART (see Appendix at http://www.aidsonline.com).
Toxicities
The incidence of NRTI toxicities and quality-of-life decrements (on a scale from 0 to 1.00, where 0 is death or worst possible health and 1.00 is perfect health) associated with these toxicities in the simulation were derived from the literature. Quality-of-life decrements were 0.08 for 3 days for mild HSR [11] , 0.15 for 7 days for severe HSR [12] , and 0.36 for 15 days for fatal HSR [7] . The probability of nephrotoxicity severe enough to require tenofovir discontinuation was derived from a clinical trial that reported an incidence of 1.1% in patients on tenofovir for 1 year [13] . Consistent with the low risk of tenofovir discontinuation in those initially tolerating the drug [14] , the incidence of nephrotoxicity was halved in each subsequent year. The average time patients spent on tenofovir-containing first-line regimens in the model was 7.9 years, resulting in an estimated cumulative incidence of discontinuations due to renal events of 2.1% during first-line treatment. Nephrotoxicity requiring tenofovir discontinuation was assumed to cause a quality-of-life decrement equivalent to mild HSR. Additional chronic toxicities considered in the model included lipoatrophy and neuropathy (see Appendix at http://www.aidsonline.com).
Costs
In the primary analysis, the cost of HLA-B Ã 5701 testing was $68, derived from the Medicare fee schedule and the Medicare reimbursement codes used by one national commercial laboratory (LabCorp, Burlington, North Carolina, USA) [15, 16] . The monthly costs of abacavir and lamivudine fixed-dose combination with efavirenz ($1135), tenofovir, emtricitabine, and efavirenz fixeddose combination ($1139), and zidovudine and lamivudine fixed-dose combination with efavirenz ($1081) are average wholesale prices, adjusted to reflect discounts to Medicaid programs and a $4 per month retail pharmacy dispensing fee for each efavirenz or fixed-dose combination prescription [8, 17] . The monthly costs of subsequent regimens ranged from $1549 to $3338 (see Appendix at http://www.aidsonline.com).
The cost of mild HSR treated in an outpatient setting was $105, based on costs of a follow-up clinic visit, a complete blood count, a blood culture, and chemistries that included tests for renal function and liver enzymes, all from Medicare fee schedules [16, 18] . For severe HSR, costs for nonfatal ($3566) and fatal ($31 999) cases were equivalent to the costs of treating similar acute events in the CEPAC model [8] . The cost of treatment-limiting nephrotoxicity was $194, based on costs of a follow-up clinic visit, a complete blood count, a urinalysis, and a chemistry panel that included a test for renal function and phosphorus (which would be repeated monthly for 6 months) [16, 18] .
Assumptions
We assumed that the probability of an unconfirmed HSR diagnosis is not affected by the prevalence of the HLA-B Ã 5701 allele in the population, and that patients with unconfirmed HSR incur the same cost and quality-of-life effects as patients with immunologically confirmed mild HSR. Because immunologic confirmatory testing (i.e., skin patch testing) is not recommended as a clinical tool [6] , we also assumed that skin patch testing would not occur and that either tenofovir and emtricitabine or zidovudine and lamivudine would be substituted for abacavir and lamivudine in these patients, depending on the strategy being evaluated.
Patients who failed on an abacavir-based treatment were assumed to have developed abacavir resistance and could not reuse this drug on subsequent regimens. Patients who failed on a regimen containing tenofovir and emtricitabine could reuse this drug combination in order to retain the beneficial effects of resistance mutations that typically emerge with these drugs [19] , unless they developed treatment-limiting tenofovir-associated nephrotoxicity.
Patients who could use neither abacavir nor tenofovir in subsequent regimens used zidovudine-based treatment and, in the event of discontinuation of zidovudine due to toxicity, were treated with lamivudine along with other active agents.
Sensitivity analyses
Because the prevalence of HLA-B Ã 5701 and the incidence of unconfirmed HSR vary by race [5, 20] , we examined the impact of simulating a population whose race/ethnicity composition is relevant in US clinical settings, instead of the European and Australian individuals enrolled in the PREDICT-1 trial. In this analysis, the cohort had a racial and ethnic composition equivalent to patients initiating HIV treatment at HIV Research Network sites in the United States (49.6% black, 27.2% white, 20.6% Hispanic, and 2.6% other race/ethnicity) [21] , with a probability of testing HLA-B Ã 5701 positive of 2.1% in blacks and 6.2% in whites, Hispanics, and those of other race/ethnicity [22] , resulting in an average prevalence of 4.1%. This analysis also took into account the observation that whites are twice as likely to receive an unconfirmed HSR diagnosis compared with nonwhites [5] , but the proportion of patients with a positive or negative test result for HLA-B Ã 5701 who develop confirmed HSR is unaffected by race/ethnicity [23] . We also considered a population restricted to patients with HIV RNA less than 100 000 copies/ml at initiation of first-line ART due to recent data finding a lower efficacy of abacavir and lamivudine in patients with initial HIV RNA more than 100 000 copies/ml [24] . To evaluate the impact of other data uncertainties, we conducted sensitivity analyses using wide ranges of plausible input data (Tables 1 and 2) . Sensitivity analyses varying efficacy of treatment Universal testing remained preferred to strategies that involve starting patients on tenofovir-based treatment in terms of cost-effectiveness only if both treatments were assumed to be equally effective. If the proportion of patients with HIV RNA less than 400 copies/ml at 48 weeks was 1% lower on abacavir-based treatment than on tenofovir-based treatment, universal testing resulted in a lower discounted quality adjusted life expectany (16.22 QALYs) than starting patients on tenofovir-based treatment. It also resulted in a higher lifetime cost, because the lower cost of the abacavir-based regimen was offset by the need to switch sooner to a more expensive therapy. A dominated strategy has a higher cost and an equal or lower quality-adjusted life expectancy compared with the previous strategy.
Results
Primary analysis
least $3 less than tenofovir-based therapy ( Table 4) . At five times the primary analysis test cost ($340), roughly equivalent to the highest cost reported by a hospital-based laboratory, initiating tenofovirbased treatment, and substituting abacavir without HLA-B Ã 5701 testing if treatment-limiting nephrotoxicity occurs, was the most cost-effective strategy compared with no testing. The incremental costeffectiveness of universal testing compared with initiating tenofovir-based treatment was $480 000/QALY. When the monthly cost of abacavir-based therapy was $6 less than tenofovir-based therapy (instead of $4 per month less in the primary analysis), universal testing became preferred to initiating with tenofovirbased treatment and had a cost-effectiveness ratio of $128 300/QALY.
Sensitivity analyses varying population characteristics
Results were similar for patients with racial/ethnic characteristics comparable with patients initiating HIV treatment in the United States. The rank ordering of results did not change, but the cost-effectiveness ratio for universal testing compared with no testing increased to $45 200/ QALY, reflecting the higher proportion of nonwhites tested and the lower prevalence of HLA-B Ã 5701 in this population (4.1 versus 5.7% in the primary analysis). Results were also similar if the population was restricted to patients with HIV RNA less than 100 000 copies/ml at initiation of first-line ART ( Table 4 ).
Results varied according to the prevalence of HLA-B Ã 5701 in the population (Fig. 1 Compared with tenofovir-based first-line therapy; 'Dominated' indicates that universal HLA-BM5701 testing has lower QALY and a higher cost compared to tenofovir-based first-line therapy. analysis test cost of $68, the cost-effectiveness ratio of universal testing remained below $100 000/QALYas long as the prevalence of HLA-B Ã 5701 was greater than 1.4% and it remained below $50 000/QALY as long as the prevalence of HLA-B Ã 5701 was greater than 3.6%, as compared with 5.7% in the primary analysis. At twice the primary analysis test cost, these thresholds became 2.9 and 7.4%.
Other sensitivity analyses
If HLA-B Ã 5701 testing eliminated all unconfirmed HSR diagnoses, universal testing became more attractive, with a cost-effectiveness ratio of $33 500/QALY assuming the primary analysis test cost. Conversely, when testing provided no benefit in reducing the probability of unconfirmed HSR diagnoses, the cost-effectiveness ratio increased to $38 700/QALY (Table 4 ). Results were sensitive to the probability of confirmed HSR among HLA-B Ã 5701 positive patients when test costs were higher: at twice the primary analysis test cost, the probability of confirmed HSR among HLA-B Ã 5701 positive patients must be below 59.1% (versus 47.9% in the primary analysis) to be cost-effective at the $50 000/QALY threshold.
As long as the monthly cost of abacavir-based treatment was at least $2 lower than tenofovir-based treatment, the universal testing strategy had a lower discounted lifetime cost than tenofovir-based treatment. Varying the proportions of confirmed HSR that were mild, severe, and fatal within published ranges did not have a meaningful impact on cost-effectiveness findings nor did varying the cost or quality-of-life decrements associated with HSR or tenofovir-related nephrotoxicity. If patients unable to use abacavir or tenofovir substituted new regimens without any risk of additional toxicities, the cost-effectiveness of universal testing became $35 000/QALY compared with $36 700/QALY in the primary analysis.
Discussion
For some medications, pretreatment genetic screening can significantly improve drug safety [25] . In HIV therapy, important new discoveries are emerging that describe genetic associations with severe adverse drug events [26] . Although genetic screening can reduce the incidence of toxicity, additional expenditures are required to conduct the genetic test. Cost-effectiveness analysis can assist decision-makers in evaluating the value of conducting pharmacogenetic tests.
We conducted a cost-effectiveness analysis of pharmacogenetic testing in HIV-infected patients in the United States, taking into account the implications for initial regimen selection and subsequent treatment options. We found that HLA-B Ã 5701 testing to guide selection of a first-line ART regimen is cost-effective, with a cost-effectiveness ratio below the commonly accepted thresholds in the United States of $50 000-$100 000/ QALY. The results were critically dependent on the comparable efficacy and lower cost of abacavir-based treatment compared with tenofovir-based treatment.
We found that the economic value of testing also depends on the cost of the test and the prevalence of HLA-B Ã 5701, although a higher test cost could be offset by a reduction in the price of abacavir-based treatment. In non-US settings, treatment and testing costs will vary depending on the site and prevalence will vary depending on the race/ethnicity characteristics of the population. The findings reported here are consistent with an analysis conducted in the United Kingdom before the PREDICT-1 results became available, which found that the incremental cost of testing per abacavir hypersensitivity reaction avoided was sensitive to prevalence and medication costs (when test costs were not varied) [27] . In the United States, cost considerations may be particularly important for public programs such as the AIDS Drug Assistance Programs funded by the Ryan White CARE Act. These state-administered programs are major payers for HIV drugs, but do not generally pay for laboratory tests, and in some states tight budget limits have already led to cost-containment strategies.
The present analysis has several limitations, and follow-up cost-effectiveness analyses will be valuable as uncertainties regarding therapeutic options and future genetic tests are resolved. We project long-term survival based on sequential lines of ART of varying efficacy based on data available from clinical trials; the actual regimens to be chosen in the future remain unknown, especially in light of recently approved agents with novel mechanisms of action. We did not take into account the possibility of increased risks of cardiovascular events associated with abacavir reported recently [28] , and we did not consider alternatives to HLA-B Ã 5701 testing that may be less expensive but have similar test performance characteristics in predicting abacavir hypersensitivity reactions. A less expensive test may result in a more attractive costeffectiveness ratio, depending on the test characteristics.
The assumption about the reduction in the rate of HSR diagnoses after testing may be conservative, because it was derived from the PREDICT-1 trial in which clinicians were blinded to whether patients experiencing symptoms had tested HLA-B Ã 5701 negative or had been assigned to the control arm. Although we found that the costeffectiveness results were only moderately sensitive to this assumption, our model does not fully reflect the benefits to providers and patients of avoiding such a diagnosis, including fewer physician-patient contacts and fewer worries about a potentially life-threatening adverse event.
Most importantly, we found that HLA-B Ã 5701 testing was only cost-effective under the assumption of equal efficacy between abacavir-based therapy and tenofovirbased therapy. In one randomized, prospective study of first-line ART [29] , abacavir/lamivudine was found to be noninferior to tenofovir/emtricitabine when both were used in combination with ritonavir-boosted lopinavir. Our findings were unchanged when we restricted the analysis to patients with HIV RNA less than 100 000 copies/ml, based on interim results from a second blinded study that is still underway [24] . However, if this study's results ultimately demonstrate a lower efficacy overall of abacavir/lamivudine regardless of baseline HIV RNA, then starting with a tenofovir-based treatment is more cost effective, regardless of whether HLA-B Ã 5701 testing is performed.
On the basis of the currently available data, use of genetic testing for HLA-B Ã 5701 to guide selection of initial treatment for HIV in the United States is effective and is cost-effective using a threshold of $50 000/QALY. However, the cost-effectiveness ratio is highly dependent on the comparable efficacy of abacavir-based treatment to tenofovir-based treatment, on the relative costs of the drugs, and on the cost of the HLA-B Ã 5701 test itself. With the many highly effective options for initial HIV treatment now available in the United States, pharmaceutical manufacturers and test providers need to ensure that the cost of this innovation is commensurate with the value that it provides.
The cost-effectiveness of HLA-BM5701 genetic screening to guide initial antiretroviral therapy for HIV: appendix CEPAC model Details regarding the CEPAC model structure, data, and assumptions have been previously described [1] [2] [3] [4] . Briefly, the model tracks each simulated patient's clinical course on a monthly basis from the time of entry into the model until death. At the time of death, the model records summary statistics for each patient (including total months of life and quality-adjusted life, and total lifetime costs) and a new patient enters the model. For these analyses, the process was repeated 10 million times for each treatment strategy to obtain stable estimates of longterm outcomes.
A simulated patient can be in one of three health states in any given month: chronic, acute, or death. In the chronic state, patients may experience disease progression and immune system deterioration depending on treatment efficacy. Patients enter a temporary acute state when they develop an opportunistic infection. In the acute state, patients have lower quality of life, higher resource utilization, and higher mortality rates. Patients in the chronic and acute states can die due to HIV-related causes or unrelated causes. Chronic and acute states are characterized by CD4 cell count; HIV RNA level; time on antiretroviral therapy; history and treatment of opportunistic infections; and prophylaxis against opportunistic infections. CD4 cell count determines HIVrelated morbidity and mortality, and in the absence of successful antiretroviral therapy the level of HIV RNA determines the rate of CD4 cell count decline [5] .
Successful antiretroviral therapy results in a regimenspecific monthly probability of maintaining HIV RNA suppression and an increase in CD4 cell count derived from published clinical trial data. Antiretroviral therapy also has a protective effect against morbidity and mortality independent of its effect on CD4 cell count [6] . HIV RNA and CD4 cell counts are monitored every 3 months, and a detected and confirmed failure to maintain HIV RNA suppression or a CD4 cell count decrease by !50% from the maximum level results in a switch to the next sequential antiretroviral drug regimen. An HIV resistance test is performed prior to the initiation of each antiretroviral regimen [7] . Opportunistic infection prophylaxis, which lowers the incidence of specific opportunistic infection acute events, is initiated according to current guidelines based on CD4 cell count or the incidence of a new opportunistic infection [8] .
Model input data
Simulated patients failing first-line ART receive up to 5 subsequent sequential lines of therapy: 2 ritonavirboosted protease-inhibitor-based regimens, 1 integrase inhibitor-based regimen, 1 CCR5 entry inhibitor-based regimen for patients with CCR5-tropic HIV or fusion inhibitor-based regimen for patients with non-CCR5tropic HIV, and a final, minimally effective background regimen that was continued until the patient's death.
The virologic efficacy of each line of antiretroviral therapy after the first line was estimated using published clinical trial data (Table 1 ) [9] [10] [11] [12] [13] , and the progression of HIV infection once all lines of therapy have been used is derived from the Multicenter AIDS Cohort Study [14] . The monthly costs of antiretroviral regimens are average wholesale prices adjusted to reflect discounts to Medicaid programs and a $4 per month retail pharmacy dispensing fee per single drug or fixed-dose combination prescription (Table 1) [2, 15] .
Direct costs of treatment for routine medical care and acute illnesses are estimated by combining data on the utilization of inpatient and outpatient medical services in each health state with data on the cost per day of inpatient and outpatient care [2] . The costs of HIV RNA, CD4 cell count, and HIV resistance tests are from the 2006 Medicare fee schedule [16] . Quality of life data for chronic HIV are derived from the HIV Cost and Services Utilization Study [17] , and for acute health states from ACTG clinical trials [18] . In the primary analysis, we took into account quality-of-life decrements associated with pancreatitis, lipoatrophy, and neuropathy occurring on alternative NRTIs for simulated patients who could not use abacavir-or tenofovir-based regimens ( Table 1 ) [19] [20] [21] [22] [23] [24] [25] [26] .
Detailed model results Figure 1 shows the possible combinations of first-line regimen toxicities (mild, severe, fatal, or suspected HSR; severe tenofovir-associated nephrotoxicity; no toxicity), initial drug regimens, and drug substitutions that could occur for each of the five initial treatment strategies. Table 2 presents the model results for each of these outcomes and the probability weights applied to these results for each strategy in the primary analysis. 
